XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

CARLYLE <CG.O> TARGETING MARKET VALUE OF 300 BLN YEN ($2.1 BLN) FOR RIGAKU, SAY SOURCES



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Carlyle-backed Japan testing-tool maker Rigaku preparing to IPO, sources say</title></head><body>

By Miho Uranaka, Kane Wu and Sam Nussey

TOKYO, Sept 19 (Reuters) -Japan's Rigaku, a maker of X-ray testing tools backed by buyout firm Carlyle Group CG.O, is preparing for a domestic initial public offering (IPO) in October, two sources familiar with the matter said.

Carlyle is targeting a market value for Rigaku of around 300 billion yen ($2.09 billion) in the IPO, one of the sources and a third source said.

A listing is not certain and, depending on market conditions, may be cancelled or rescheduled, one of the sources said.

Japan's stock market suffered a historic rout in early August sparked by a surprise rate hike and fears of a U.S. recession, before regaining ground.

Nomura, Morgan Stanley and Bank of America are joint global coordinators, two of the sources said.

Rigaku, Carlyle, Nomura, Morgan Stanley and Bank of America declined to comment. The sources declined to be identified as the information is not public.

Carlyle will sell shares in the IPO, the sources said.

Subway operator Tokyo Metro and chipmaker Kioxia are both targeting listings in October, Reuters has reported.

Carlyle announced in January 2021 it was acquiring a roughly 80% stake in Rigaku through its fourth Japan buyout fund, with the company's then-CEO Hikaru Shimura holding a roughly 20% stake.

Rigaku said at the time it is targeting growing demand for X-ray equipment due to the miniaturisation of semiconductors and electronic components, and aims to list in the coming years.

The growing complexity of chip manufacturing processes is driving the need for testing with Rigaku's tools, which are offered for research and development, and production.

Rigaku also sells its equipment to industries such as materials science and pharmaceuticals.

Founded in 1951, Rigaku booked revenue of 80 billion yen in 2023, up around a quarter from a year earlier, and makes 70% of its sales overseas.

Rigaku's peers include Spectris-owned SXS.L Malvern Panalytical, located in Britain, and U.S.-based Bruker BRKR.O.

Jun Kawakami, formerly an executive at General Electric and Arteria Networks, became CEO last year, with Shimura serving as chairman.

Buyout firms are making deals in Japan as companies shed non-core assets, go private, or management grapples with a lack of successors.

Carlyle's other investments in Japan include KFC Japan, Iwasaki Electric and Orion Breweries.

The firm said in May it has raised 430 billion yen in its largest ever investment vehicle for Japan.

($1 = 143.4800 yen)



Reporting by Miho Uranaka and Sam Nussey in Tokyo and Kane Wu in Hong Kong; Editing by Muralikumar Anantharaman

</body></html>

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.